News & Videos - ACTICOR BIOTECH

You are currently viewing all stock exchange news of the financial instrument ACTICOR BIOTECH regarding all markets in all languages.

> News GlobeNewsWire published a news.

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack • • GlobeNewsWire • Stocks

University of Birmingham and Acticor Biotech News Release Limited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attacks February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction. In 2022, the University of Birmingham and...

Thank you Chart

> News GlobeNewsWire published a news.

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke • • GlobeNewsWire • Stocks

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in the United-States, Europe, Israel and United Kingdom Confirmation of clinical results communication for the second quarter 2024 Paris, France, November 07, 2023 - 08h00 CET - ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the...

Thank you Chart

> News GlobeNewsWire published a news.

Acticor adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke • • GlobeNewsWire • Stocks

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024 Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028 Paris, France, September 14, 2023 - 5.45 pm CEST - Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of July 31, 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of July 31, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority). Listing Place: Euronext Growth...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 juillet 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), entreprise biopharmaceutique au stade clinique spécialisée dans le développement de médicaments innovants pour le traitement des urgences cardio-vasculaires, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 31 juillet 2023. Place de cotation : Euronext Growth Paris Code ISIN : FR0014005OJ5...

Thank you Chart

> News Business Wire published a news.

Acticor Biotech: Half-Year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux. Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2023: - 43,423...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LA SOCIÉTÉ DE BOURSE KEPLER CHEUVREUX • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique spécialisée dans le développement de médicaments innovants pour le traitement des urgences cardio-vasculaires, annonce aujourd’hui son bilan semestriel de son contrat de liquidité contracté avec la société de Bourse Kepler Cheuvreux. Au titre du contrat de liquidité confié par la société ACTICOR BIOTECH à Kepler Cheuvreux, à la date du 30 juin 2023, les moyens suivants...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of June 30, 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of June 30, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority). Listing Place: Euronext Growth Paris ISIN Code...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 juin 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique spécialisée dans le développement de médicaments innovants pour le traitement des urgences cardio-vasculaires, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 30 juin 2023. Place de cotation : Euronext Growth Paris Code ISIN : FR0014005OJ5 Site web :...

Thank you Chart

> News Business Wire published a news.

Acticor Biotech : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique spécialisée dans le développement de médicaments innovants pour le traitement des urgences cardio-vasculaires, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 31 mai 2023. Place de cotation : Euronext Growth Paris Code ISIN : FR0014005OJ5 Site web :...

Thank you Chart

> News Business Wire published a news.

Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of May 31, 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of May 31, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority). Listing Place: Euronext Growth Paris ISIN Code...

Thank you Chart

> News Business Wire published a news.

Acticor Biotech : Avancées des discussions avec les Agences Réglementaires européennes et américaines • • Business Wire • Stocks

Regulatory News: Acticor Biotech, (ISIN : FR0014005OJ5 - ALACT), entreprise biopharmaceutique au stade clinique qui développe glenzocimab, un médicament innovant pour le traitement des urgences cardiovasculaires, notamment les accidents vasculaires cérébraux ischémiques, échange avec la FDA et l'EMA sur son programme de développement dans l'indication de l'accident vasculaire cérébral (AVC) ischémique aigu. Aux États-Unis, Acticor Biotech a obtenu de la FDA une consultation de type C...

Thank you Chart

> News Business Wire published a news.

Acticor Biotech: Progress in Discussions with EU and US Regulatory Agencies • • Business Wire • Stocks

Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, is discussing with the FDA and the EMA its development program for the acute ischemic stroke (AIS) indication. In the US, Acticor Biotech was granted FDA Type C consultation on its non-clinical and clinical developments for its first-in-class drug candidate, glenzocimab. Written responses were...

Thank you Chart

> News Business Wire published a news.

Participation d’Acticor Biotech à l’ESOC 2023, premier forum européen pour la recherche sur l'AVC • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique qui développe glenzocimab, un médicament innovant pour le traitement des urgences cardiovasculaires, notamment les accidents vasculaires cérébraux ischémiques, annonce avoir participé à l' European Stroke Organization Conference (ESOC) 2023 les 24, 25 et 26 mai 2023 à Munich en Allemagne. L' ESOC est le premier forum européen pour la recherche sur l'AVC et la plateforme de choix...

Thank you Chart

> News Business Wire published a news.

Participation of Acticor Biotech in ESOC 2023, first European Forum for Stroke Research • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces today that it will participate in the European Stroke Organization Conference (ESOC) 2023 on May 24, 25 and 26, 2023 in Munich, Germany. ESOC is the leading European forum for stroke research and the preferred platform for the publication of major clinical trial data. At this...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH: Report of the Combined General Meeting of May 12, 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today released the report of its Combined General Meeting held on May 12, 2023 The shareholders attending the meeting, represented by proxy or voting by post held 10,638,244 votes, representing a quorum of 86.5%. All resolutions of this Combined General Meeting were adopted, with the...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH : Compte rendu de l’Assemblée Générale Mixte du 12 mai 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique qui développe glenzocimab, un médicament innovant pour le traitement des urgences cardiovasculaires, notamment les accidents vasculaires cérébraux ischémiques, publie aujourd'hui le compte rendu de son Assemblée Générale Mixte du 12 mai 2023. Les actionnaires présents, représentés ou ayant voté par correspondance détenaient 10 638 244 voix, soit un quorum de 86,5%. L’ensemble...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of April 30, 2023 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority). Listing Place: Euronext Growth Paris ISIN...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 avril 2023 • • Business Wire • Stocks

Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique spécialisée dans le développement de médicaments innovants pour le traitement des urgences cardio-vasculaires, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 30 avril 2023. Place de cotation : Euronext Growth Paris Code ISIN : FR0014005OJ5 Site web :...

Thank you Chart

> News Business Wire published a news.

ACTICOR BIOTECH : Mise à disposition du Document d’enregistrement universel 2022 et des documents préparatoires relatifs à l’assemblée générale mixte du 12 mai 2023 • • Business Wire • Stocks

Regulatory News : ACTICOR BIOTECH (FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique qui développe glenzocimab, un médicament innovant pour le traitement des urgences cardiovasculaires, notamment les accidents vasculaires cérébraux ischémiques, annonce aujourd'hui la mise à disposition de son Document d’enregistrement universel 2022 ainsi que des documents préparatoires à son Assemblée générale mixte du 12 mai 2023. Mise à disposition du document...

Thank you Chart

1
2

NEW !